| Business Summary | | Access
Pharmaceuticals,
Inc.
is
a
development-stage
pharmaceutical
company
focused
on
developing
both
novel
low-development
risk
product
candidates,
and
technologies
with
longer-term
major
product
opportunities.
The
Company
has
proprietary
patents
or
rights
to
five
technology
platforms:
synthetic
polymers,
bioerodible
hydrogels,
Residerm,
carbohydrate-targeting
technology
and
agents
for
the
prevention
and
treatment
of
viral
disease,
including
HIV.
Its
partner,
GlaxoSmithKline
is
marketing
Aphthasol
in
the
United
States,
a
drug
jointly
developed
for
the
treatment
of
canker
sores.
The
Company
has
licensed
certain
of
the
rights
to
amlexanox
for
the
treatment
of
canker
sores
from
GlaxoSmithKline
for
certain
countries
and
the
worldwide
rights
for
additional
indications,
including
mucositis
and
oral
diseases.
The
Company
is
also
developing
Polymer
Platinate,
a
chemotherapeutic
agent
believed
to
have
significantly
reduced
toxicity
and
superior
efficacy
in
treating
cancers. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Access
Pharmaceuticals
provides
drug
delivery
systems
through
the
design
of
polymer/drug
complexes
to
control
site
directed
targeting,
localized
release
and
clearance
of
therapeutic
drugs,
imaging
agents
and
radiopharmaceuticals.
For
the
six
months
ended
6/30/01,
revenues
totaled
$221
thousand
vs.
none.
Net
loss
rose
6%
to
$2.7
million.
Results
reflect
license
revenues
related
to
ResiDerm
and
amlexanox,
offset
by
increased
clinical
development
expenses
for
the
OraRinse. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Herbert McDade, Jr., 74 Chairman | -- | Kerry Gray, 48 Pres,
CEO | $411K | Stephen Thompson, 47 CFO,
VP, Treasurer | 126K | David Nowotnik, Ph.D., 52 VP
R&D | 260K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|